Yevgeniy Vinogradskiy1, Leah Schubert2, Quentin Diot2, Timothy Waxweiller2, Phillip Koo3, Richard Castillo4, Edward Castillo5, Thomas Guerrero5, Chad Rusthoven2, Laurie Gaspar2, Brian Kavanagh2, Moyed Miften2. 1. Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado. Electronic address: yevgeniy.vinogradskiy@ucdenver.edu. 2. Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado. 3. Department of Radiology, University of Colorado School of Medicine, Aurora, Colorado. 4. Department of Radiation Oncology, University of Texas Medical Branch, Galveston, Texas. 5. Department of Radiation Oncology, Beaumont Health System, Royal Oak, Michigan.
Abstract
PURPOSE: The development of clinical trials is underway to use 4-dimensional computed tomography (4DCT) ventilation imaging to preferentially spare functional lung in patients undergoing radiation therapy. The purpose of this work was to generate data to aide with clinical trial design by retrospectively characterizing dosimetric and functional profiles for patients with different stages of lung cancer. METHODS AND MATERIALS: A total of 118 lung cancer patients (36% stage I and 64% stage III) from 2 institutions were used for the study. A 4DCT-ventilation map was calculated using the patient's 4DCT imaging, deformable image registration, and a density-change-based algorithm. To assess each patient's spatial ventilation profile both quantitative and qualitative metrics were developed, including an observer-based defect observation and metrics based on the ventilation in each lung third. For each patient we used the clinical doses to calculate functionally weighted mean lung doses and metrics that assessed the interplay between the spatial location of the dose and high-functioning lung. RESULTS: Both qualitative and quantitative metrics revealed a significant difference in functional profiles between the 2 stage groups (P<.01). We determined that 65% of stage III and 28% of stage I patients had ventilation defects. Average functionally weighted mean lung dose was 19.6 Gy and 5.4 Gy for stage III and I patients, respectively, with both groups containing patients with large spatial overlap between dose and high-function regions. CONCLUSION: Our 118-patient retrospective study found that 65% of stage III patients have regionally variant ventilation profiles that are suitable for functional avoidance. Our results suggest that regardless of disease stage, it is possible to have unique spatial interplay between dose and high-functional lung, highlighting the importance of evaluating the function of each patient and developing a personalized functional avoidance treatment approach.
PURPOSE: The development of clinical trials is underway to use 4-dimensional computed tomography (4DCT) ventilation imaging to preferentially spare functional lung in patients undergoing radiation therapy. The purpose of this work was to generate data to aide with clinical trial design by retrospectively characterizing dosimetric and functional profiles for patients with different stages of lung cancer. METHODS AND MATERIALS: A total of 118 lung cancerpatients (36% stage I and 64% stage III) from 2 institutions were used for the study. A 4DCT-ventilation map was calculated using the patient's 4DCT imaging, deformable image registration, and a density-change-based algorithm. To assess each patient's spatial ventilation profile both quantitative and qualitative metrics were developed, including an observer-based defect observation and metrics based on the ventilation in each lung third. For each patient we used the clinical doses to calculate functionally weighted mean lung doses and metrics that assessed the interplay between the spatial location of the dose and high-functioning lung. RESULTS: Both qualitative and quantitative metrics revealed a significant difference in functional profiles between the 2 stage groups (P<.01). We determined that 65% of stage III and 28% of stage I patients had ventilation defects. Average functionally weighted mean lung dose was 19.6 Gy and 5.4 Gy for stage III and I patients, respectively, with both groups containing patients with large spatial overlap between dose and high-function regions. CONCLUSION: Our 118-patient retrospective study found that 65% of stage III patients have regionally variant ventilation profiles that are suitable for functional avoidance. Our results suggest that regardless of disease stage, it is possible to have unique spatial interplay between dose and high-functional lung, highlighting the importance of evaluating the function of each patient and developing a personalized functional avoidance treatment approach.
Authors: Y Seppenwoolde; S H Muller; J C Theuws; P Baas; J S Belderbos; L J Boersma; J V Lebesque Journal: Int J Radiat Oncol Biol Phys Date: 2000-06-01 Impact factor: 7.038
Authors: Martin T King; Peter G Maxim; Maximilian Diehn; Billy W Loo; Lei Xing Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-28 Impact factor: 7.038
Authors: Douglas Brennan; Leah Schubert; Quentin Diot; Richard Castillo; Edward Castillo; Thomas Guerrero; Mary K Martel; Derek Linderman; Laurie E Gaspar; Moyed Miften; Brian D Kavanagh; Yevgeniy Vinogradskiy Journal: Int J Radiat Oncol Biol Phys Date: 2015-03-25 Impact factor: 7.038
Authors: Lindsay Mathew; Andrew Wheatley; Richard Castillo; Edward Castillo; George Rodrigues; Thomas Guerrero; Grace Parraga Journal: Acad Radiol Date: 2012-09-19 Impact factor: 3.173
Authors: Iram Munawar; Brian P Yaremko; Jeff Craig; Michael Oliver; Stewart Gaede; George Rodrigues; Edward Yu; Robert Henderson Reid; Eugene Leung; Jean-Luc Urbain; Jeff Chen; Eugene Wong Journal: Med Phys Date: 2010-04 Impact factor: 4.071
Authors: Judith A Christian; Mike Partridge; Elena Nioutsikou; Gary Cook; Helen A McNair; Bernadette Cronin; Frederic Courbon; James L Bedford; Michael Brada Journal: Radiother Oncol Date: 2005-11-07 Impact factor: 6.280
Authors: Brian P Yaremko; Thomas M Guerrero; Josue Noyola-Martinez; Rudy Guerra; David G Lege; Linda T Nguyen; Peter A Balter; James D Cox; Ritsuko Komaki Journal: Int J Radiat Oncol Biol Phys Date: 2007-03-29 Impact factor: 7.038
Authors: Douglas A Hoover; Dante Pi Capaldi; Khadija Sheikh; David A Palma; George B Rodrigues; A Rashid Dar; Edward Yu; Brian Dingle; Mark Landis; Walter Kocha; Michael Sanatani; Mark Vincent; Jawaid Younus; Sara Kuruvilla; Stewart Gaede; Grace Parraga; Brian P Yaremko Journal: BMC Cancer Date: 2014-12-11 Impact factor: 4.430
Authors: Elizabeth M Jaffee; Chi Van Dang; David B Agus; Brian M Alexander; Kenneth C Anderson; Alan Ashworth; Anna D Barker; Roshan Bastani; Sangeeta Bhatia; Jeffrey A Bluestone; Otis Brawley; Atul J Butte; Daniel G Coit; Nancy E Davidson; Mark Davis; Ronald A DePinho; Robert B Diasio; Giulio Draetta; A Lindsay Frazier; Andrew Futreal; Sam S Gambhir; Patricia A Ganz; Levi Garraway; Stanton Gerson; Sumit Gupta; James Heath; Ruth I Hoffman; Cliff Hudis; Chanita Hughes-Halbert; Ramy Ibrahim; Hossein Jadvar; Brian Kavanagh; Rick Kittles; Quynh-Thu Le; Scott M Lippman; David Mankoff; Elaine R Mardis; Deborah K Mayer; Kelly McMasters; Neal J Meropol; Beverly Mitchell; Peter Naredi; Dean Ornish; Timothy M Pawlik; Jeffrey Peppercorn; Martin G Pomper; Derek Raghavan; Christine Ritchie; Sally W Schwarz; Richard Sullivan; Richard Wahl; Jedd D Wolchok; Sandra L Wong; Alfred Yung Journal: Lancet Oncol Date: 2017-10-31 Impact factor: 41.316
Authors: Eunsin Lee; Jing Zeng; Robert S Miyaoka; Jatinder Saini; Paul E Kinahan; George A Sandison; Tony Wong; Hubert J Vesselle; Ramesh Rengan; Stephen R Bowen Journal: Med Phys Date: 2017-06-01 Impact factor: 4.071
Authors: Yevgeniy Vinogradskiy; Richard Castillo; Edward Castillo; Leah Schubert; Bernard L Jones; Austin Faught; Laurie E Gaspar; Jennifer Kwak; Daniel W Bowles; Timothy Waxweiler; Jingjing M Dougherty; Dexiang Gao; Craig Stevens; Moyed Miften; Brian Kavanagh; Inga Grills; Chad G Rusthoven; Thomas Guerrero Journal: Int J Radiat Oncol Biol Phys Date: 2021-11-09 Impact factor: 7.038
Authors: Wei Shao; Taylor J Patton; Sarah E Gerard; Yue Pan; Joseph M Reinhardt; Oguz C Durumeric; John E Bayouth; Gary E Christensen Journal: IEEE Trans Med Imaging Date: 2019-12-30 Impact factor: 10.048
Authors: Daniel Rocky Owen; Phillip S Boonstra; Benjamin L Viglianti; James M Balter; Matthew J Schipper; William C Jackson; Issam El Naqa; Shruti Jolly; Randall K Ten Haken; Feng-Ming Spring Kong; Martha M Matuszak Journal: Int J Radiat Oncol Biol Phys Date: 2018-06-01 Impact factor: 7.038
Authors: Hannah Mary T Thomas; Jing Zeng; Howard J Lee; Balu Krishna Sasidharan; Paul E Kinahan; Robert S Miyaoka; Hubert J Vesselle; Ramesh Rengan; Stephen R Bowen Journal: Br J Radiol Date: 2019-08-12 Impact factor: 3.039
Authors: Jingjing M Dougherty; Edward Castillo; Richard Castillo; Austin M Faught; Mark Pepin; Sean S Park; Chris J Beltran; Thomas Guerrero; Inga Grills; Yevgeniy Vinogradskiy Journal: J Appl Clin Med Phys Date: 2021-06-22 Impact factor: 2.102
Authors: Wei Shao; Yue Pan; Oguz C Durumeric; Joseph M Reinhardt; John E Bayouth; Mirabela Rusu; Gary E Christensen Journal: Med Image Anal Date: 2021-06-21 Impact factor: 13.828